SCHEMBL12430709

SCHEMBL12430709

CC1=NN(c2cccc(Cl)c2)C(=O)/C1=C\NNC(=O)c1ccccc1[N+](=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 2/20 0.43
PTPN1 P18031 1/20 0.43
DHFR P00374 2/20 0.42
KMT2A Q03164 10/20 0.41
MEN1 O00255 7/20 0.41
MAPT P10636 6/20 0.41
MAPK1 P28482 4/20 0.41
ALDH1A1 P00352 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
HTT P42858 2/20 0.41
MDM2 Q00987 1/20 0.41
GPR55 Q9Y2T6 1/20 0.41
L3MBTL1 Q9Y468 4/20 0.41
RAB9A P51151 1/20 0.40
GAA P10253 2/20 0.38
KAT8 Q9H7Z6 2/20 0.38
POLB P06746 2/20 0.37
NSD2 O96028 1/20 0.37
HSPA1A P0DMV8 1/20 0.37
TNNI3 P19429 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14599446 0.94 EP300 (0.43) EP300PTPN1DHFRKMT2AMEN1
SCHEMBL14629657 0.92 MEN1 (0.46) EP300PTPN1DHFRKMT2AMEN1
SCHEMBL12430708 0.88 KMT2A (0.44) EP300KMT2AMEN1MAPTMAPK1
SCHEMBL12430720 0.83 KMT2A (0.53) EP300PTPN1DHFRKMT2AMEN1
SCHEMBL14629554 0.82 EP300 (0.52) EP300KMT2AMEN1MAPTMAPK1
SCHEMBL12430724 0.81 KMT2A (0.44) EP300KMT2AMEN1MAPTMAPK1
SCHEMBL14599447 0.81 KMT2A (0.47) EP300KMT2AMEN1MAPTMAPK1
SCHEMBL2203157 0.80 MEN1 (0.51) EP300KMT2AMEN1MAPTALDH1A1
SCHEMBL12510448 0.79 EP300 (0.51) EP300KMT2AMEN1MAPTMAPK1
SCHEMBL12430715 0.76 KMT2A (0.48) EP300KMT2AMEN1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977366-B2 Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation CORNELL RESEARCH FOUNDATION, INC. (US) 2011-07-12 US disclosed
US-20070021448-A1 Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021448-A1 Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation MPO, MMP8, SERPINB1 EP300 1342/4885PTPN1 1479/4885DHFR 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.